LLY vs OSCR

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Oscar Health Inc. continues to demonstrate strong momentum and validate its 10x growth potential. The most significant development since the last analysis is CEO Mark T. Bertolini's substantial $11.92 million share purchase, signaling high insider confidence and reinforcing the company's strategic direction. This, combined with favorable 2027 Medicare rate hikes and a subsequent 22% stock rally, b...